MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have received an average rating of “Moderate Buy” from the twelve brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $74.46.

A number of research firms recently weighed in on MLTX. Wedbush reaffirmed an “outperform” rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a report on Wednesday, March 13th. Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 9th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 23rd. William Blair reissued an “outperform” rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, February 26th. Finally, Wolfe Research began coverage on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 15th. They issued an “outperform” rating and a $77.00 target price on the stock.

MoonLake Immunotherapeutics Trading Down 1.6 %

NASDAQ:MLTX opened at $44.52 on Tuesday. MoonLake Immunotherapeutics has a 12 month low of $24.31 and a 12 month high of $64.98. The company has a market capitalization of $2.84 billion, a P/E ratio of -58.58 and a beta of 1.29. The firm has a fifty day simple moving average of $46.54 and a 200-day simple moving average of $50.91.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.11. Equities analysts forecast that MoonLake Immunotherapeutics will post -1.11 EPS for the current year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 4,740 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $55.89, for a total transaction of $264,918.60. Following the completion of the transaction, the chief executive officer now owns 2,982,814 shares in the company, valued at approximately $166,709,474.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Da Silva Jorge Santos sold 4,740 shares of MoonLake Immunotherapeutics stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $55.89, for a total transaction of $264,918.60. Following the completion of the transaction, the chief executive officer now directly owns 2,982,814 shares of the company’s stock, valued at $166,709,474.46. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Kristian Reich sold 10,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $60.15, for a total transaction of $601,500.00. Following the completion of the sale, the insider now directly owns 110,071 shares in the company, valued at $6,620,770.65. The disclosure for this sale can be found here. Over the last quarter, insiders sold 166,981 shares of company stock worth $9,490,674. 12.02% of the stock is owned by insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $51,000. PNC Financial Services Group Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 50.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock worth $371,000 after purchasing an additional 2,067 shares during the period. Barclays PLC acquired a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at about $189,000. Stratos Wealth Partners LTD. purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $202,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in MoonLake Immunotherapeutics during the 4th quarter worth approximately $217,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.